Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

metastasis

- PMLiVE

UK drug repurposing study identifies several potential dementia treatments

An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

- PMLiVE

Common antidiabetic drug metformin found to slow growth of precancerous cells

The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Study identifies thousands of high-risk cancer gene variants and potential therapeutic target

Patients with inherited variants of the BAP1 gene have a 50% increased risk of developing certain cancers

- PMLiVE

Researchers’ new vaccine technology shows efficacy against broad range of coronaviruses

The vaccine provided protection against coronaviruses that have not yet emerged

- PMLiVE

New immune cell discovery could lead to personalised breast cancer treatments

The study revealed the key features of immune cells in helping the body’s immune system fight cancer

- PMLiVE

UK study reveals significantly higher risk of second cancers among breast cancer survivors

Breast cancer is currently the most commonly diagnosed cancer in the UK, affecting around 56,000 people annually

- PMLiVE

UK universities awarded over £58m by Cancer Research UK for clinician scientist training

The funding builds on the charity’s previous Clinical Academic Training Programme Award investment in 2019

- PMLiVE

Single genetic test could replace current standard for diagnosing rare developmental disorders

The single genetic test could potentially replace the current standard and reduce costs for the NHS

- PMLiVE

ICR study shows how dormant breast cancer cells can be targeted to prevent relapse

Oestrogen receptor positive breast cancer accounts for up to 80% of all breast cancers cases

- PMLiVE

Study reveals molecular signatures driving immune cell attacks in chronic neurological diseases

MS is a chronic neurological disease that affects more than two million people worldwide

- PMLiVE

Cambridge study reveals potential biomarker and target for long COVID treatments

The pro-inflammatory molecule, IFN-Y, persisted until symptoms improved in patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links